Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (111-120 of 156) with videos related to

Pageof 16
Sort By:
Haematologica|May 12, 2018
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>Sergio Storti, Michele Spina, Emanuela Anna Pesce, et al.
Hematological Oncology|June 17, 2020
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidityLuigi Rigacci, Ombretta Annibali, Sofya Kovalchuk, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 15, 2020
Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo"Stefano Botti, Iris Agreiter, Laura Orlando, et al.
Blood|July 7, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 studyGuido Gini, Monica Tani, Alessandra Tucci, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialMarc P E André, Théodore Girinsky, Massimo Federico, et al.
Pageof 16

Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Haematologica|May 12, 2018
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>Sergio Storti, Michele Spina, Emanuela Anna Pesce, et al.
Hematological Oncology|June 17, 2020
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidityLuigi Rigacci, Ombretta Annibali, Sofya Kovalchuk, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 15, 2020
Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo"Stefano Botti, Iris Agreiter, Laura Orlando, et al.
Blood|July 7, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 studyGuido Gini, Monica Tani, Alessandra Tucci, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialMarc P E André, Théodore Girinsky, Massimo Federico, et al.
Pageof 16